Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program

VectorY Therapeutics has secured 129 million euros ($138 million) in a series A financing that will help the Dutch biotech advance its preclinical lead program in amyotrophic lateral sclerosis (ALS).